4 - Seminal Abstract
A phase III, randomized, double-blind trialof weekly paclitaxel plus the angiopoientin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1
Tuesday, March 25, 2014: 9:35 AM
Ballroom B/C (Tampa Convention Center)
B. J. Monk1, A. Poveda2, I. B. Vergote3, F. Raspagliesi4, K. Fujiwara5, D. S. Bae6, A. Oaknin7, L. Navale8, D. J. Warner8 and A. M. Oza9
1University of Arizona Cancer Center, Phoenix, AZ, 2Fundación Instituto Valenciano de Oncología, Valencia, Spain, 3University Hospital Leuven, Leuven, Belgium, 4Fondazione IRCCS Istituto Nazionale Tumori -Milan, Milan, Italy, 5Saitama Medical University International Medical Center, Hidaka-Shi, Japan, 6Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 7GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Barcelona, Spain, 8Amgen Inc., Thousand Oaks, CA, 9University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
